Peptide protocols & reference data

The first GnRH antagonist approved in the US for prostate cancer, providing immediate testosterone suppression without flare. Withdrawn from market but historically significant.

The synthetic N-terminal 24-amino-acid fragment of ACTH, retaining full adrenocortical stimulating activity. FDA approved for the Synacthen (cortisol stimulation) diagnostic test.

The full native 39-amino-acid adrenocorticotropic hormone from the anterior pituitary. Drives cortisol synthesis in the adrenal cortex. Available clinically as HP Acthar Gel for inflammatory & neurological conditions.

The natural 13-amino-acid melanocortin peptide produced by the pituitary. Acts on MC1-5 receptors with broad effects on pigmentation, inflammation, appetite, & thermoregulation.

The endogenous octapeptide vasopressor of the renin-angiotensin system. FDA approved as Giapreza for distributive shock refractory to catecholamines.

The endogenous 28-amino-acid cardiac peptide that promotes natriuresis, vasodilation, & inhibition of the renin-angiotensin-aldosterone system. Used clinically in Japan for acute heart failure.

The primary endogenous opioid peptide (31 amino acids) produced from POMC cleavage. Binds mu-, delta-, & kappa-opioid receptors with high affinity. Central mediator of pain, reward, & stress analgesia.

A stable gastric pentadecapeptide with broad regenerative & anti-inflammatory activity across musculoskeletal, gut, & neurological tissue.

A synthetic GnRH agonist used for prostate cancer, endometriosis, & infertility treatment. Available as nasal spray & depot injection.

A GnRH antagonist that immediately suppresses LH & FSH without the initial testosterone flare seen with GnRH agonists. Used in IVF & is under study for BPH.

A stabilized Growth Hormone-Releasing Hormone analog with a 30-minute half-life, producing clean physiological GH pulses without the extended clearance of DAC-modified versions.

A GHRH analog modified with a Drug Affinity Complex that covalently binds albumin, extending half-life to 8–10 days. Produces continuous GH elevation rather than pulsatile release.

A synthetic tetrapeptide bioregulator developed from cortical tissue extracts. Studied for neuroprotection, cognitive support, & regulation of cortical function.

A somatostatin-related neuropeptide with additional anti-inflammatory, slow-wave sleep-promoting, & anxiolytic properties not shared by classical somatostatin.

The hypothalamic 41-amino-acid neuropeptide that drives ACTH release from the pituitary, initiating the stress response axis. Research tool for HPA axis assessment.

A GnRH antagonist for prostate cancer that suppresses testosterone to castrate levels within 3 days without initial flare — faster than GnRH agonists.

A highly selective delta-opioid receptor agonist from frog skin (Phyllomedusa bicolor). The most selective delta-opioid ligand known — a key research tool.

A 7-amino-acid frog-skin heptapeptide with exceptionally potent mu-opioid receptor activity — 30–40x more potent than morphine. Banned in equine sport for illicit analgesic use.

A synthetic vasopressin analog with selective V2 receptor activity. FDA approved for diabetes insipidus, nocturnal enuresis, & hemophilia A/von Willebrand disease.

A potent nootropic compound that amplifies hepatocyte growth factor (HGF) signaling in the brain, promoting synaptogenesis & cognitive enhancement with effects far exceeding those of BDNF in animal models.

A nonapeptide isolated from rabbit brain that induces delta sleep, modulates stress hormones, & has shown anti-stress & analgesic properties.

A 13-amino-acid kappa-opioid receptor agonist & the predominant endogenous kappa ligand. Associated with stress-induced dysphoria, pain, & appetite regulation.

A tetrapeptide with the highest selectivity & affinity for the mu-opioid receptor of any known endogenous opioid. Research tool for understanding mu-receptor-mediated analgesia.

The second endomorphin tetrapeptide with high mu-opioid receptor selectivity & potent spinal analgesia. Complement to Endomorphin-1 with distinct CNS distribution.

A synthetic tetrapeptide pineal gland extract studied for telomerase activation, circadian normalization, & longevity in Russian gerontology research.

The first GLP-1 receptor agonist approved for clinical use, derived from the Gila monster venom peptide Exendin-4. Available in twice-daily & once-weekly formulations.

A retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, triggering their selective apoptosis. The first peptide-based senolytic.

A synthetic decapeptide GnRH antagonist used in IVF to prevent premature LH surges, providing an alternative to GnRH agonist down-regulation protocols.

A naturally occurring tripeptide-copper complex with wound healing, anti-aging, anti-inflammatory, & collagen-stimulating activity across multiple tissue types.

A potent hexapeptide GH secretagogue with strong pulse output & moderate cortisol/prolactin elevation. Preferred over GHRP-6 when appetite stimulation is undesirable.

One of the original GH-releasing peptides with potent ghrelin-pathway activity & pronounced appetite stimulation — useful in bulking or muscle wasting contexts.

The native 10-amino-acid gonadotropin-releasing hormone. Stimulates LH & FSH release from the pituitary. Used in fertility treatment & TRT to maintain testicular function.

The most potent GH-releasing hexapeptide. Produces the highest GH peak of any GHRP but desensitizes faster & elevates cortisol/prolactin significantly.

The lipolytic C-terminal fragment of human growth hormone that retains fat-burning activity without GH's anabolic, IGF-1-elevating, or hyperglycemic effects.

A GnRH agonist delivered via subcutaneous implant releasing medication for 12 months. Approved for prostate cancer & central precocious puberty.

A 21-amino-acid peptide encoded in mitochondrial 16S rRNA with cytoprotective, anti-apoptotic, & insulin-sensitizing properties linked to longevity & Alzheimer's protection.

A truncated form of IGF-1 lacking the first three amino acids, with 10x higher potency than native IGF-1 & a shorter half-life. Primarily used for local muscle injections.

A recombinant IGF-1 analog with an N-terminal arginine extension & Glu substitution at position 3 that reduces IGFBP binding & extends half-life to 20–30 hours.

A selective GH secretagogue with clean pulse kinetics & minimal cortisol or prolactin elevation. The safest & most widely used GH-releasing peptide.

The endogenous C-terminal decapeptide of Kisspeptin-54 that potently stimulates GnRH secretion. Used in research to trigger the LH surge & study HPG axis function.

A 13-amino-acid bioactive form of kisspeptin with similar GnRH-stimulating activity to KP-10. Research tool for HPG axis studies.

The full-length 54-amino-acid kisspeptin precursor with longer half-life & sustained GnRH-stimulating activity. The endogenous form used in human fertility & HPG axis research.

A C-terminal tripeptide of alpha-MSH with potent anti-inflammatory activity via NF-kB inhibition. Used orally or by injection for gut inflammation & systemic inflammatory conditions.

A long-acting somatostatin analog administered as a deep subcutaneous depot every 4 weeks. Approved for acromegaly & gastroenteropancreatic neuroendocrine tumors.

One of the two endogenous enkephalin pentapeptides, acting primarily on delta-opioid receptors with rapid enzymatic degradation in plasma.

A widely used long-acting GnRH agonist for prostate cancer, endometriosis, uterine fibroids, & precocious puberty. One of the most commercially important peptide drugs.

A once-daily GLP-1 analog FDA approved for both type 2 diabetes & obesity. The predecessor to semaglutide with a well-established long-term safety record.

The only human cathelicidin antimicrobial peptide. Kills pathogens directly, modulates inflammation, promotes wound healing, & has angiogenic & anti-tumor properties.

A cyclic melanocortin analog with potent tanning, libido-enhancing, & appetite-suppressing effects via MC1R, MC3R, MC4R, & MC5R agonism.

The methionine-containing endogenous enkephalin pentapeptide. Acts on delta- & zeta-opioid receptors & also has immunomodulatory & anti-tumor properties as opioid growth factor (OGF).

A splice variant of IGF-1 produced locally by muscle tissue in response to mechanical stress. Activates satellite cells & promotes local muscle repair & hypertrophy.

A 16-amino-acid peptide encoded in mitochondrial DNA that activates AMPK, improves insulin sensitivity, & shows dramatic lifespan extension in mouse models.

A GnRH agonist administered as a nasal spray, approved for endometriosis & central precocious puberty.

The endogenous ligand of the NOP (nociceptin/orphanin FQ) receptor, the fourth opioid receptor family member. Modulates pain, anxiety, stress response, & addiction.

A synthetic somatostatin analog with potent inhibition of GH, glucagon, insulin, & GI peptide secretion. Used for acromegaly, carcinoid syndrome, & VIPomas.

The endogenous 9-amino-acid nonapeptide produced in the hypothalamus governing social bonding, trust, uterine contraction, & lactation. Used clinically for labor induction.

A multireceptor-targeted somatostatin analog with broader SSTR binding than octreotide. FDA approved for Cushing's disease & acromegaly refractory to first-line treatment.

PEGylated form of MGF with a half-life of several days instead of minutes. Enables non-workout-timed dosing & systemic distribution.

A synthetic tripeptide (Glu-Asp-Pro) developed from pineal gland extracts with neuroprotective, anti-aging, & cognitive-supporting properties.

An FDA-approved melanocortin agonist for hypoactive sexual desire disorder in women, & widely used off-label for sexual function in both sexes.

An investigational triple agonist of GLP-1, GIP, & glucagon receptors showing 24% mean weight loss in Phase II — the highest in any clinical peptide trial to date.

A synthetic heptapeptide based on the tuftsin fragment with anxiolytic, nootropic, & immune-modulating effects. Approved in Russia for anxiety & stress disorders.

A once-weekly GLP-1 analog with FDA approval for type 2 diabetes & obesity. The most widely verified peptide in the Certipep ledger.

A synthetic heptapeptide ACTH analog developed in Russia with cognitive-enhancing, neuroprotective, & BDNF-upregulating properties. Approved for stroke & cognitive deficit treatment.

The native GHRH 1-29 sequence approved for clinical GH deficiency diagnosis & treatment. The oldest & most clinically validated GH secretagogue.

An FDA-approved selective MC4R agonist for rare genetic obesity disorders including POMC, PCSK1, & LEPR deficiency. The most targeted melanocortin anti-obesity drug.

The native 14-amino-acid hypothalamic hormone that inhibits GH, insulin, glucagon, & multiple GI peptides. The parent molecule for all somatostatin analogs.

A cardiolipin-targeting tetrapeptide that protects the inner mitochondrial membrane, reduces oxidative stress, & improves mitochondrial efficiency in aging & disease.

A synthetic analog of Thymosin Beta-4 with systemic tissue remodeling, anti-fibrotic, & angiogenic effects. The go-to peptide for systemic recovery & cardiac tissue repair.

An FDA-approved GHRH(1-44) analog for HIV-associated lipodystrophy. The most clinically validated GHRH analog with proven visceral fat reduction.

A polypeptide thymus extract with immunomodulatory & anti-aging properties. Used in Russian & Eastern European medicine for immune reconstitution & longevity.

An FDA-approved 28-amino-acid thymic peptide that enhances innate & adaptive immunity. Used clinically for hepatitis B/C, cancer adjuvant therapy, & immune deficiency.

A once-weekly dual GIP/GLP-1 receptor agonist with superior weight loss efficacy versus GLP-1 monotherapy. FDA approved for T2D & obesity.

The tripeptide hypothalamic hormone that triggers TSH release from the pituitary. Used diagnostically to assess pituitary thyroid reserve.

A synthetic GnRH agonist that produces initial LH/FSH surge followed by pituitary desensitization, driving medical castration. Used in prostate cancer, endometriosis, & precocious puberty.

A synthetic somatostatin analog studied for variceal bleeding & carcinoid syndrome. Available in some European countries.

The endogenous antidiuretic hormone controlling water reabsorption, blood pressure, & social memory. Used clinically for diabetes insipidus & septic shock.

A 28-amino-acid neuropeptide with broad vasodilatory, anti-inflammatory, & immune-modulatory effects. Studied for pulmonary arterial hypertension & inflammatory disorders.